Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › rozanolixizumab

rozanolixizumab

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of rozanolixizumab

8 trials tracked of rozanolixizumab: 4 in phase 3 or 4 and 4 with published results. The most-cited published study has 294 citations.

8Trials tracked
4Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 3 4 Phase 2 3 Phase 1 1
  1. Phase 3 A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis Completed · 294 cited
  2. Phase 3 A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis Completed · 291 cited
  3. Phase 3 A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis Completed · 291 cited
  4. Phase 3 A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG) Completed · 3 cited
  5. Phase 2 A Proof-of-concept Study to Evaluate the Efficacy and Safety of Rozanolixizumab to Treat Adult Study Participants With Severe Fibromyalgia Syndrome Completed
  6. Phase 2 A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Completed
Show 2 more trials
  1. Phase 2 A Study to Assess Long-term Safety, Tolerability and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Completed
  2. Phase 1 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Rozanolixizumab Administered Subcutaneously Via Manual Push Versus Syringe Driver to Healthy Participants Completed

Showing the 8 most-cited and recently-updated of 8 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Mechanistic-driven diagnosis and therapy shift focus from platelet counts to underlying pathophysiology of thrombocytopenia
Hematology Sys. Review
Mechanistic-driven diagnosis and therapy shift focus from platelet counts to underlying pathophysiology of thrombocytopenia New Framework Offers Precise Treatment for Low Blood Platelets
This systematic review synthesizes the multidimensional pathogenesis of thrombocytopenia across five axes including production, immune-media…
A new diagnostic framework moves beyond simple blood counts to identify the specific cause of low platelets for more precise treatment.
Frontiers Sep 29, 2026
PLEX and corticosteroids show highest clinical response rates in chronic inflammatory demyelinating polyradiculoneuropathy
Pediatrics Meta-analysis
PLEX and corticosteroids show highest clinical response rates in chronic inflammatory demyelinating polyradiculoneuropathy New FcRn Inhibitors Show Promise for Chronic Inflammatory Neuropathy
This systematic review and network meta-analysis of 2,184 patients evaluated various treatments for chronic inflammatory demyelinating polyr…
Newer treatments like efgartigimod alfa may offer significant clinical responses and improved grip strength for patients with chronic inflam…
Frontiers Sep 15, 2026
Complement inhibitors and FcRn blockers improve outcomes in AChR-Ab+ generalized myasthenia gravis
Oncology Meta-analysis
Complement inhibitors and FcRn blockers improve outcomes in AChR-Ab+ generalized myasthenia gravis New Drugs Double Your Chance of Getting Better
A meta-analysis of 739 adults in RCTs and 588 in OLEs with acetylcholine receptor antibody-positive generalized myasthenia gravis found that…
New drugs for generalized myasthenia gravis double the odds of meaningful improvement while reducing the need for rescue therapy and severe …
Apr 14, 2026